Companies · Biotechnology

Lazarus 3D, Inc.

Albany · Biotechnology

Diligence memoA one-page analyst read on Lazarus 3D, Inc. — recommendation, valuation, rhythm, risks.
$6.0M
Total raised · real
1
Rounds
Latest step-up
Top 54%
Sector rank · raised
Series A
Latest stage · inferred · Fri Apr 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Lazarus 3D, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.11× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Lazarus 3D, Inc. is one of 4293 Biotechnology companies tracked from Albany. By capital raised it ranks mid-pack (ahead of 47% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
16
Investors (latest)
2021
Year incorporated
2022-04-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeries A · 2022-04-01 Raised $6.0M (real) Modeled valuation $94M (est)$6.0M$94MSeries A2022

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.0M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$93.6M
Base estimate est.
$6.6M
Conservative case
$340.3M
Upside case
$27.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
4.3 yr
Elapsed time used
4.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
4.3 yr
On record since
2022
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$6.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$6.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.5× above median
This company$93.6M
Sector median$64.2M

Raised more than 47% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #56 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Lazarus 3D, Inc. (this company) Raised $6.0M · modeled $93.6M (est)Lazarus 3D, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Lazarus 3D, Inc. this companySeries A$6.0M$93.6M2.11×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.0M2022-04-01$27.4M$93.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.0M2022-04-01
    • First recorded raise — entered as Series A.
    • 16 investors on this round.
Intelligence
Modeled next raise
$9.6M
Modeled next size est.range $6.3M$15.4M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jacques Eric Zaneveld2022-04
Smriti Eric Zanefeld2022-04
Registry & provenance

Lazarus 3D, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1690281
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Amberstone Biosciences, Inc.BiotechnologySeries A$6.0M$112.7Msame sector · same stage
Radicle Science, Inc.BiotechnologySeries A$6.0M$106.4Msame sector · same stage
Sinaptic Holdings, LLCBiotechnologySeries A$5.6M$88.0Msame sector · same stage
Markman Biologics CorpBiotechnologySeries A$6.5M$103.9Msame sector · same stage
DNAlite Therapeutics, Inc.BiotechnologySeries A$5.6M$87.1Msame sector · same stage
CorriXR Therapeutics, Inc.BiotechnologySeries A$6.5M$90.1Msame sector · same stage
Redesign Science IncBiotechnologySeries A$6.7M$112.0Msame sector · same stage
Secretome Therapeutics, Inc.BiotechnologySeries A$6.9M$78.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
3D Bio Holdings, Inc.BiotechnologySeries A$181.8M89%
ChemoSen3D, Inc.BiotechnologyPre-Seed$6.8M86%
MH3D, Inc.BiotechnologySeed$11.9M85%
3X Genetics Inc.BiotechnologySeed$14.5M84%
Third Arc Bio, Inc.BiotechnologySeries C$636.7M84%
Neonc Technologies Holdings, Inc.BiotechnologySeries C$51.9M84%
Mosaic Biosciences, Inc.BiotechnologySeries A$176.4M84%
Jupiter Biomedical Research, Inc.BiotechnologyPre-Seed$844K83%
Frequently asked
How much funding has Lazarus 3D, Inc. raised?
Lazarus 3D, Inc. has raised approximately $6.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Lazarus 3D, Inc.'s estimated valuation?
Provath's modeled valuation for Lazarus 3D, Inc. is approximately $93.6M (modeled range $6.6M–$340.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Lazarus 3D, Inc. at?
Lazarus 3D, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Apr 01.
What does Lazarus 3D, Inc. do and where is it based?
Lazarus 3D, Inc. operates in the Biotechnology sector, based in Albany.
Explore related

See where Lazarus 3D, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Lazarus 3D, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.